Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2022 · 10-Q
Revenue$3.93M$3.93M+62.4% vs Q1 2021 Net Income-$5.99M-$5.99MN/M vs Q1 2021 EPS Diluted-$0.16-$0.16N/M vs Q1 2021 Gross Profit$1,291,263+149.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$4,675,886N/M Free Cash Flowderived-$4,675,886— Margins · derivedGross margin32.9%+11.5 pt vs Q1 2021
Operating margin-144.8%+43.4 pt vs Q1 2021
Net margin-152.7%+31.1 pt vs Q1 2021
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end